Replies to post #67575 on Biotech Values

[DewDiligence]

>what do you think will happen to prasugrel?<

If The Pink Sheet is right and Prasugrel isin fact going to an advisory panel in early 2009, my wild guess is a 65% chance of approval on the first review cycle. Of course, this number may go up or down sharply when the briefing docs are made public.